Product Information

CAS No.	251579-55-2
Product Name	Abt-510

Associated Conditions

Hodgkins lymphoma·non-small cell lung carcinoma·neoplasm·cutaneous melanoma·sarcoma·

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology • Vol. 17, Issue 8 • 2006

PMID: 16728485 DOI: 10.1093/annonc/mdl102

Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 12, Issue 24 • 2006

PMID: 17189418 DOI: 10.1158/1078-0432.CCR-06-0109

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 11, Issue 18 • 2005

PMID: 16166447 DOI: 10.1158/1078-0432.CCR-05-0621

Abt-510

CAS No.	251579-55-2
MDL No.	N/A
MF	C₄₆H₈₃N₁₃O₁₁
MW	994.20
InChI Key	RIWLPSIAFBLILR-WVNGMBSFSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	251579-55-2
Product Name	Abt-510

Associated Conditions

Hodgkins lymphoma·non-small cell lung carcinoma·neoplasm·cutaneous melanoma·sarcoma·

* The information provided here is compiled from public sources and is for reference only.

Abt-510

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Abt-510

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

Abt-510

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Similar Products

Rapastinel

Tetrapeptide-1

Kentsin

Davunetide

H-Cys(1)-Arg-Thr-Ile-Gly-Pro-Ser-Val-Cys(1)-OH

MBP Ac1-9

Abt-510

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Similar Products

Rapastinel

Tetrapeptide-1

Kentsin

Davunetide

H-Cys(1)-Arg-Thr-Ile-Gly-Pro-Ser-Val-Cys(1)-OH

MBP Ac1-9

Documentation